Loading clinical trials...

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation | Clinical Trials | Clareo Health

UNKNOWN

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

Clinical Study on the Efficacy of Modified Liujunzi Prescription on the Treatment of Atrophic Gastritis After HP Eradication

NCT05388890•Peking University First Hospital

View on ClinicalTrials.gov

Summary

This is an observational cohort study of clinical efficacy study.The purpose of this topic is to evaluate the efficacy and safety of Modified Liujunzi Decoction based on syndrome differentiation in patients with chronic atrophic gastritis(CAG) after HP eradication.Taking Modified Liujunzi Decoction as the observation group and Weifuchun routine treatment as the control group, so as to provide evidence for the treatment of CAG and reduce the risk of gastric cancer. A total of 284 patients were included. The curative efficacy, symptom score and adverse events will be recorded and analyzed.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with CAG diagnosed by endoscopy and pathological examination, the pathological diagnosis criteria refer to the China consensus of chronic gastritis (2017) ;
•Previous HP infection, HP negative after standardized treatment;
•TCM syndrome differentiation mainly focuses on the weakness of the spleen and stomach,referring to the consensus on the diagnosis and treatment of chronic atrophic gastritis with integrated traditional Chinese and Western Medicine (2017), there is no restriction on concurrent syndrome;
•Age 18-70 years old, regardless of gender;
•The subject (or legal representative) voluntarily agreed and signed the informed consent form, and was able to abide by the study protocol during the study.

Exclusion Criteria

•History of gastric surgery;
•Combined with serious diseases affecting the study evaluation, such as serious liver disease, heart disease, kidney disease, malignant tumor and alcoholism;
•Allergic to the drugs used in this study;
•Participated in clinical research of other drugs in the first 3 months of the study;
•Patients can't express correctly their subjective feelings and can't cooperate.

Locations (1)

Peking University First Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

August 2, 2022

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2025

Last Updated

September 5, 2023

Enrollment

286

ESTIMATED participants

Conditions

Chronic Atrophic Gastritis

Interventions

MLD

DRUG

WFC

DRUG

Contacts

Qiuyue Huang, doctor

CONTACT

+86010 83572351 1711210349@pku.edu.cn

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

NCT03261934

Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation

View study

UNKNOWNEARLY_PHASE1

Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis

NCT05493124

Chronic Atrophic Gastritis

View study

UNKNOWN

Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation

NCT03314038

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

Inclusion Criteria

Exclusion Criteria

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis

Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation

Clinical Study of Weifuchun Treatment on Precancerous Lesions of Gastric Cancer

Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)

To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG)